📢 PRESS RELEASE 📢 #ARCHIMED’s MED II sells DIESSE Diagnostica Senese S.p.A., returning 4.6x to shareholders. ARCHIMED announces the sale of #DIESSE to private equity firm Fremman Capital. The transaction caps a five-year partnership with #DIESSE and marks the latter’s transformation into a leading clinical diagnostics innovator. The deal returns 4.6 times invested capital to shareholders. To read the full Press Release, please visit our hashtag #ARCHIMED website 👇 https://lnkd.in/dZDJVBuQ #ARCHIMED #ImpactingHealthcare #IVD #DIESSE
ARCHIMED
Directeurs du capital-risque et du capital-investissement
Lyon, Auvergne-Rhone-Alpes 25 416 abonnés
Impacting Healthcare
À propos
With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.
- Site web
-
http://www.archimed.group
Lien externe pour ARCHIMED
- Secteur
- Directeurs du capital-risque et du capital-investissement
- Taille de l’entreprise
- 51-200 employés
- Siège social
- Lyon, Auvergne-Rhone-Alpes
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2014
- Domaines
- Diagnostics, Consumer Health, Pharma Services, Biopharma Products, MedTech, Healthcare IT, Life Science Tools et Biologic Services
Lieux
-
Principal
Obtenir l’itinéraire
9 rue des Cuirassiers
69003 Lyon, Auvergne-Rhone-Alpes, FR
-
Obtenir l’itinéraire
152 W 57th St
59/F
10019 New York, US
Employés chez ARCHIMED
-
Wendy White
Independent Board Director, CEO, Private Equity Strategic Advisor, Rare Disease, Woman's Health, Medical Device
-
Markus Sandmayr
CEO international / FMCG/ BCorp/ Business Angel/ Administrateur de Société/ France Europe
-
Berthold Hackl
Healthcare & Life Sciences: Strategy and Transactions
-
Dr. Michael Williams
Board Member, Advisor, Invester
Nouvelles
-
📢 ARCHIMED announces the successful divestiture of Stragen's unit STRAGEN SERVICES SAS 📢 In a strategic development, STRAGEN SERVICES SAS, known for its pharmacovigilance and clinical safety expertise, will join ProductLife Group (PLG), a renowned player in Lifescience consulting, with strong expertise in regulatory compliance. #ARCHIMED #ImpactingHealthcare #Stragen #StragenServices #PLG
📢 @Stragen Services is excited to announce the alliance with ProductLife Group (PLG), a global provider of regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry. Joining PLG is a strategic and exciting step for Stragen Services, our team, our clients, and our partners. PLG’s commitment to excellence, integrity, and client-focused partnerships mirrors our values. This alliance strengthens our ability to deliver top-notch international safety solutions both in pre- and post-marketing, and better support our clients in combination with PLG’s integrated global infrastructure. 👉 For more information, please read our full Press Release here. #LifeSciences #Healthcare #Pharma #consulting #leader #Productlifegroup
-
ARCHIMED’s 10th year was a remarkable year. In our "LOOKING BACK AT 2024" video, you will find out more about how we FUND healthcare industries🧬🔬💊globally, how we SUPPORT healthcare entrepreneurs in their companies’ development 🚀and how we deliver a superior RETURN to our investors 📈and to society🌍. As we step into #2025, #ARCHIMED is more than ever committed to delivering positive health outcomes to patients👨👩👧👦, directly or indirectly, whether through better efficacy, safety, efficiency, affordability or accessibility. #ARCHIMED #ImpactingHealthcare #health #patientoutcome
-
NAMSA announces the acquisition of the US Medical Device Testing Operations of WuXi AppTec, strengthening its position as the leader in MedTech testing and clinical research. #ARCHIMED #ImpactingHealthcare #NAMSA #WuXiAppTec #MedTech
🚀 Big News! NAMSA has entered into a definitive agreement to acquire WuXi AppTec's U.S. Medical Device Testing Operations. With facilities in Minnesota and Georgia, this acquisition enhances our ability to offer comprehensive solutions to our clients. Together, we aim to accelerate MedTech innovation and deliver life-saving medical technology worldwide. Stay tuned for more updates as we work closely with WuXi AppTec to ensure a smooth transition for employees and clients. Learn more about our journey: https://lnkd.in/getCFmDU #NAMSA #MedTech #Innovation #Acquisition #Healthcare #WuXiAppTec
-
-
ARCHIMED's ActiGraph has announced the acquisition of Biofourmis Connect, a division of Biofourmis that delivers an AI-driven, digital trial platform tailored for the life science industry. This strategic acquisition enables ActiGraph to deliver the industry's most comprehensive digital health solution, supporting a wide range of clinical use cases with a device-agnostic platform and patient-centric approach, and strengthening further its position in the digital health technology. ⌚️💻📈 #ARCHIMED #ImpactingHealthcare #ActiGraph #Biofourmis #healthtech #digitalhealth #lifescience
📣 Big news!! We are excited to announce that ActiGraph has acquired the Biofourmis Connect digital trial platform, accelerating our vision of bringing best-in-class, clinically validated digital solutions for scalable deployment in clinical development. This combined solution positions #ActiGraph to offer the most comprehensive and trusted digital health solution in the life science industry through - ✅ A device-agnostic platform supporting a variety of sensor modalities & form factors ✅ Real-time collection of continuous, high-precision digital data ✅ A suite of AI-based and regulatory-cleared algorithms ✅ End-to-end support backed by operational, analytical, and regulatory expertise The new combined solution will create a market-leading, unified software and data ecosystem for the modernization of clinical research. We look forward to helping our customers improve clinical development productivity to get the right treatments to the right patients, faster. Read the full press release ➡️ https://hubs.la/Q031p7Zl0 #DigitalHealth #DigitalData #AI #Acquisition #ClinicalDevelopment #ClinicalTrials
-
-
📢 PRESS RELEASE 📢 #ARCHIMED finalizes a transformational deal for Cube Biotech with the acquisition of IBA Lifesciences. This strategic acquisition highlights Cube Biotech’s vision to accelerate innovation, streamline services, and expand global outreach, following several key partnerships already concluded in the past 12 months. To read the full Press Release, please visit our #ARCHIMED website 👇 https://lnkd.in/dxc2RfGV #ARCHIMED #ImpactingHealthcare #Lifescience #Cubebiotech #IBAlifesciences
-
-
📢 PRESS RELEASE 📢 #ARCHIMED earns 5x its investment, selling a majority of Ad-Tech Medical Instrument Corporation to Tokyo-listed Nihon Kohden Corporation and announces joint venture with the company to pursue Ad-Tech’s growth in North America, Europe, and Asia. To read the full Press Release, please visit our #ARCHIMED website 👇 https://lnkd.in/dukh6pzk #ARCHIMED #ImpactingHealthcare #MedTech #AdTech #NihonKohden
-
-
📢 PRESS RELEASE 📢 #ARCHIMED invests in SeqCenter. #SeqCenter is a category leader in Next-Generation Sequencing (NGS), which can sequence hundreds of thousands of genes in record-time and at low cost. To read the full Press Release, please visit our #ARCHIMED website 👇 https://lnkd.in/d24GywQh #ARCHIMED #ImpactingHealthcare #IVD #Diagnostics #SeqCenter
-
-
📢 PRESS RELEASE 📢 #ARCHIMED announces the acquisition of FIM Medical, the leader in the occupational health medical devices market in France, with a strong international footprint. An acquisition nicely complementing our existing MedTech companies Micromed, Natus Neuro, Natus Sensory or Ad-Tech Medical Instrument Corporation. To read the full Press Release, please visit our #ARCHIMED website 👇 https://lnkd.in/dU7JcjZw #ARCHIMED #ImpactingHealthcare #MedTech #FIMMedical
-
-
🎙 Episode 4/4 of our #ARCHIMED athletes' interview series 🎙 => Closing our 3 minutes series with Manasi Joshi 🏸, an amazing athlete and inspiring person. 🙏 Thanks Manasi Joshi 🏸 🙏 Elena Semechin 🏊♂️ , Benjamin LACROIX-DESMAZES 🏐, Manasi Joshi 🏸and NoahMalone Track 🏃♂️ 🏅#ARCHIMED Coubertin Project, partnering for excellence, passion and team spirit. 🏅